28.04.2025 • News
Merck to Acquire US Biopharma Company SpringWorks Therapeutics
Merck and biopharmaceutical company SpringWorks Therapeutics, have entered into a definitive agreement for Merck to acquire SpringWorks.
Merck
04.07.2024 • News
Merck Partners with Afrigen Biologics on mRNA Vaccines
German chemicals, pharmaceuticals and life sciences group Merck entered a non-binding Memorandum of Understanding (MoU) with Afrigen Biologics to support the development of an mRNA vaccine technology platform. The collaboration is aimed at advancing mRNA platform manufacturing capabilities, scaling up production, optimizing processes, and providing troubleshooting expertise, the companies said.
Decarbonizing for a Sustainable Future
Reducing greenhouse gas (GHG) emissions in the supply chain lies outside of a company’s direct control, so collaboration with suppliers and partners in the supply chain is key.
21.05.2024 • Whitepaper
Transition Metals in Catalysis: From Precious to Practical
Download this complimentary Article Collection today!
The Future of mRNA Technology
mRNA-based vaccines against the coronavirus have become firmly established in medicine since the pandemic. Nevertheless, the technology is still at the beginning of its potential. Experts see a wide range of potential applications for this relatively new technology, particularly in infectious diseases and cancer.
28.02.2024 • News
Merck Opens New €20 Million Distribution Center in Brazil
Merck will open a new € 20 million distribution center in São Paulo, Brazil to better serve its Life Science customers in the region. The new space, which will be operational in late February, has an area of 13,000 square meters, which is twice as large as the former São Paulo location.
29.01.2024 • News
Merck Establishes Digital Hub in Singapore
German chemicals, pharmaceuticals and life sciences group Merck has opened a digital hub in Singapore, the first outside of the US and Europe for its digital business.
15.11.2023 • News
Merck to Relocate US Healthcare Headquarters to Boston
German chemicals, pharmaceuticals and life sciences group Merck, which operates its Healthcare business as EMD Serono in the US and Canada, announced that it plans to move its US Healthcare headquarters, currently located in Rockland, Massachusetts, to Boston’s Seaport district.
03.07.2023 • News
Abcam Attracts Interest from US Life Sciences Giants
Abcam, a biotech supplier, has garnered interest from major US life sciences companies Danaher and Agilent as it explores its potential sale. The company has also approached Germany’s Merck and attracted attention from large buyout firms, say sources of Bloomberg.
30.06.2023 • News
Germany’s Merck Expanding Reagents in China
As part of an agreement with China’s Nantong Economic and Technological Development Area (NETDA), Germany’s Merck said it plans to spend €70 million to expand production capacity for highly-purified reagents at its site in the Chinese city of the same name, a major transportation hub in the Yangtze River Delta region.
20.06.2023 • News
FTC Intervention in Amgen-Horizon Deal Stuns Biopharma
The US Federal Trade Commission’s lawsuit to potentially block the $27.8 merger of Amgen and Horizon Therapeutics is creating heightened concern in the international biopharma sector.
05.06.2023 • News
Merck Invests in Scottish Biosafety Unit
Germany’s Merck is investing €35 million in biosafety testing at its Glasgow and Stirling sites in Scotland. When completed – no date has been given – the company said the expansion will create nearly 500 jobs, lifting the workforce headcount across the two sites to more than 1,200.
22.05.2023 • News
German Merck Adds Renewable Energy Capacity
In what it calls another major step toward implementing its sustainability strategy, Germany’s Merck has signed a 16-year, off-site, virtual power purchase agreement (VPPA) with Recurrent Energy for its Liberty County Solar project northeast of Houston Texas, in the US.
05.05.2023 • News
Germany’s Merck Signs MoU on Korean Biotech Hub
Germany’s Merck said this week it has signed a non-binding Memorandum of Understanding (MoU) with South Korea’s Ministry of Trade, Industry and Energy (MOTIE), and Daejeon City to establish a new Asia-Pacific BioProcessing Center.
02.05.2023 • News
Glenmark Putting Chunk of API Offshoot up for Sale?
India-headquartered drugmaker Glenmark is said to be taking another look at selling a majority stake in its business with active pharmaceutical ingredients (APIs), which is wrapped up in subsidiary Glenmark Life Sciences.
28.04.2023 • News
Germany Weighs Merits of Growing China Trade
As April winds down and major German chemical companies hold their annual shareholder meetings, questions are being asked whether about the country is tying its trade too closely to with China and repeating the same mistakes it made earlier by becoming dependent on Russian gas.
19.04.2023 • News
US Merck Snaps up Prometheus Biosciences for $10.8 Billion
Shares of Prometheus Biosciences soared on news that US drugs major Merck will acquire the company in an all-cash deal valued at roughly $200 per share, or $10.8 billion.
13.04.2023 • News
Germany’s Merck to Invest in its US Chips Business
Germany’s Merck plans to invest some €300 million in an integrated specialty gas plant in Hometown, Pennsylvania, to support the development of its semiconductor business.
05.04.2023 • News
Germany’s Merck Ends Bavencio Pact with Pfizer
Germany’s Merck will regain exclusive worldwide rights to develop, manufacture and commercialize the anti-programmed death ligand-1 (PD-L1) antibody Bavencio (avelumab) following the termination of its Alliance agreement with US drugs giant Pfizer, planned for the end of the second quarter.
10.03.2023 • News
German Merck and Intel in AI Research Project
German chemicals, pharmaceuticals and life sciences group Merck and US semiconductors giant Intel have signed a letter of intent to fund a European academic research program that will leverage artificial intelligence (AI) and machine learning technologies to drive innovation.
10.01.2023 • News
German Merck Licenses Fusion Protein to PDS
Germany‘s Merck has granted an exclusive license for the tumor-targeting IL-12 fusion protein currently known as M9241 to PDS Biotechnology Corporation, a US-based clinical-stage immunotherapy company with a growing pipeline of targeted immunotherapies for cancer and infectious disease.
12.12.2022 • News
Germany’s Merck Buys Erbi Biosystems
Germany’s Merck has acquired Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology known as the Breez. Financial terms were not disclosed. The company is based in the US state of Massachusetts.
24.11.2022 • News
Germany’s Merck Realigns Drug R&D Strategy
In a move to advance productivity, the healthcare division of Germany’s Merck is realigning its drug discovery and launch strategy. Global healthcare research chief Danny Bar-Zohar told a conference call this week that the Darmstadt-based company will seek to strike a new balance between in-house R&D and external collaboration.
18.11.2022 • News
Germany’s Merck Invests in US Biosafety Test Capacity
Germany’s Merck is investing over €290 million in US biosafety testing capacity at Rockville, Maryland, to “significantly increase” its ability to meet double-digit demand growth. The largest investment in contract testing in its history will create more than 500 new jobs.
08.11.2022 • News
Pharma CEOs Take Action on Climate Change
The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.
18.10.2022 • News
Merck & Co and Moderna Proceed with Cancer Vaccine
US drugmaker Merck & Co is going ahead with plans to develop a therapeutic cancer vaccine called mRNA-4157 together with Covid vaccine maker Moderna. This fulfills an agreement first signed in 2016 and amended in 2018.
06.10.2022 • News
Millipore CTDMO Services Opens Facility in France
Millipore CTDMO Services, part of the Life Science arm of Germany’s Merck, has opened a commercial facility in France.
04.10.2022 • News
Merck Grants Sinopharm Rights to Covid Pills
US drugs giant Merck & Co has granted Sinopharm exclusive import and distribution rights to its oral Covid treatment Lagevrio (molnupiravir) in China.
30.09.2022 • News
GSK Names Julie Brown as First Female CFO
From next year, GSK’s top management will be led by a double female team, a pioneering move for the global pharmaceutical industry. The UK drugs giant this week announced the appointment of Julie Brown, the first woman to be its chief financial officer.
12.09.2022 • News
Germany’s Merck Expands French Facility
German science and technology company Merck has announced plans to invest more than €130 million at its site in Molsheim, France, to expand capacities for single-use assemblies, a key technology for producing Covid-19 vaccines and other therapies.
18.08.2022 • News
Germany’s Merck to Acquire Mecaro’s Chemicals Arm
German chemicals, pharmaceuticals and life science group Merck has signed a definitive agreement to acquire the chemical business of Mecaro, a manufacturer of heater blocks for heating wafers in the semiconductor process or glasses in the LCD (liquid crystal display) process, along with chemical precursors for semiconductors.
24.06.2022 • News
Merck Germany Doubles HPAPI Potential
The Life Science business segment of German pharmaceuticals, chemicals and life sciences group Merck has widened its US plant for high-potent active pharmaceutical ingredients (HPAPIs) at Verona, near Madison, Wisconsin to 6,500 m2.
Proactive Supplier Risk Mitigation for Manufacturing and Testing Organizations
There is a new urgency in the market for manufacturers and testing organizations to be prepared for rapid, unexpected changes in material resource access, exacerbated by turbulent regional and global events. This focus is in addition to reinforcing routine risk mitigation activities around the raw material supply chain, adding to the relevance and impact of the topic.
24.05.2022 • News
Germany’s Merck Invests €440 million in Ireland
The Life Science segment of Germany’s Merck is investing around €440 million to increase membrane and filtration manufacturing capabilities in Ireland’s County Cork. The plans call for adding capacity at an existing plant in Carrigtwohill and building a new plant in Blarney Business Park.
04.05.2022 • News
Germany’s Merck to Expand Wuxi Production Site
Germany’s Merck has signed has an agreement with the Administrative Management Committee of Wuxi National High-Tech Industrial Development Zone to “significantly expand” the company’s first Asia-Pacific Mobius Single-Use manufacturing center in China.
KPMG
Datamonitor Group
Arthur D. Little GmbH
Codexis
Mack Brooks Exhibition Ltd – Part of RX
EvaluatePharma
Thomson Reuters
SchüllerConsulting
CHEManager International c/o Wiley-VCH GmbH
PP Consulting
Evotec
ISPE D/A/CH e.V.
Merck KGaA
ARC Advisory Group GmbH & Co KG
Univers. St. Gallen
Iktos AI
CHEManager c/o Wiley-VCH Verlag GmbH & Co. KGaA
Merck & Co
Sartorius AG
Together for Sustanability (TFS)
Millipore Corporation
Merck Chemicals Co. Ltd.
Frost & Sullivan
LANXESS Deutschland GmbH